mRNA-3927
Phase 2RNA therapy
ModernamRNA-3927 is one of 41 biologic programs targeting Propionic Acidemia. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
96 competitors in ART
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Venclexta
AbbViePhase 3
Lorelco
SanofiPhase 3
Rituxan
RochePhase 3
Attruby
NNavire Pharma Inc., a BridgeBio company
Phase 3
Brukinsa
BBeOne Medicines
Phase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Cysteine Hydrochloride
NovartisPhase 2
Noradrenaline
IInstitute of Liver and Biliary Sciences, India
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mRNA-3927. EMBL-EBI & Wellcome Sanger Institute.
- [4]